Solitary plaque on the leg of a child: A report of two cases and a brief review of acral pseudolymphomatous angiokeratoma of children and unilesional mycosis fungoides

Pediatric Dermatology, EarlyView.
Source: Pediatric Dermatology - Category: Dermatology Authors: Source Type: research

Related Links:

Publication date: Available online 20 September 2019Source: Seminars in Cancer BiologyAuthor(s): Hermann A.M. MuckeABSTRACTIntellectual property documents (patents and their published applications) are not only collections of legal exclusivity claims but also repositories of scientific and technical information, even though they are not peer reviewed. We have identified and analyzed international disclosures concerning drug repurposing for cancer that were published under the Patent Convention Treaty during the past five years, and show this burgeoning field from an angle that is not routinely captured in review papers of ...
Source: Seminars in Cancer Biology - Category: Cancer & Oncology Source Type: research
Mycosis fungoides is the most common primary cutaneous T cell lymphoma, characterized by erythematous patches and plaque lesions with slow progression to cutaneous tumors or extracutaneous involvements in some patients. We aimed to evaluate the clinical characteristics, treatment responses, disease courses, and mortality rates of our MF cases. The data of 100 patients with MF were retrospectively examined from medical records in our clinic between January 2005 and January 2015. Demographic and clinical characteristics of the patients, disease stage, treatment protocols, response to treatment, recurrence, progression, and m...
Source: Acta Dermatovenerologica Croatica - Category: Dermatology Source Type: research
Conclusion: Doxycycline is not suitable as a sole agent in the treatment of early stages of classic MF, acting mainly by anti-inflammatory rather apoptotic function. PMID: 31526286 [PubMed - as supplied by publisher]
Source: Journal of Dermatological Treatment - Category: Dermatology Tags: J Dermatolog Treat Source Type: research
Authors: Guglielmo A, Filippini A, Bertuzzi C, Sabattini E, Gaspari V, Pileri A, D'antuono A Abstract PMID: 31525845 [PubMed - as supplied by publisher]
Source: Giornale Italiano di Dermatologia e Venereologia - Category: Dermatology Tags: G Ital Dermatol Venereol Source Type: research
Abstract Advanced stage mycosis fungoides (MF) and Sézary syndrome (SS) account for ~30% of patients with cutaneous T-cell lymphomas (CTCL). The prognosis is poor with a median survival of 36 months.1 Treatments rarely result in durable remissions and recent management guidelines recommend allogeneic haematopoietic stem cell transplant (HSCT) for eligible patients as the best chance of improved survival. PMID: 31536644 [PubMed - as supplied by publisher]
Source: The British Journal of Dermatology - Category: Dermatology Authors: Tags: Br J Dermatol Source Type: research
Abstract Brentuximab Vedotin (BV) is a CD30 antibody drug complex that has a direct cytotoxic effect against CD30-expressing cells including its microenvironment1 . ALCANZA, a recent phase-3 randomised controlled international clinical trial showed superior response rate with BV (67%) compared to conventional therapies (physician's choice) with either methotrexate or bexarotene (20%) in the treatment of CD30+ mycosis fungoides (MF) and primary cutaneous anaplastic large cell lymphoma (pcALCL). Furthermore, a significantly improved duration of response lasting at least 4months (ORR4) was reported in 56% of patients...
Source: The British Journal of Dermatology - Category: Dermatology Authors: Tags: Br J Dermatol Source Type: research
[Cutaneous lymphomas : Clinical presentation - diagnosis - treatment]. Hautarzt. 2019 Sep 11;: Authors: Wobser M, Goebeler M Abstract Cutaneous lymphomas comprise different subgroups with distinct biological behavior. Mycosis fungoides, the most common cutaneous lymphoma, presents with patches, plaques, tumors and erythroderma. Therapeutic options depend on stage and comprise local skin-directed treatment in early stages, while later stages and Sézary syndrome require systemic therapies including bexarotene, interferon or brentuximab vedotin. While the rare CD4-positive lymphoprolifera...
Source: Der Hautarzt: Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete - Category: Dermatology Tags: Hautarzt Source Type: research
A comparative analysis of histone deacetylase inhibitors for the treatment of mycosis fungoides and Sézary syndrome. Br J Dermatol. 2019 Sep 12;: Authors: Papps T, McCormack C, Buelens O, Van der Weyden C, Twigger R, Campbell BA, Dickinson M, Prince HM Abstract Two histone deacetylase inhibitors (HDACi), vorinostat and romidepsin have been approved by regulatory agencies in parts of the world for the treatment of relapsed/refractory Mycosis Fungoides (MF) and Sézary Syndrome (SS) based on positive Phase II trial results.1,2 Panobinostat has activity in MF/SS, and is approved in the ...
Source: The British Journal of Dermatology - Category: Dermatology Authors: Tags: Br J Dermatol Source Type: research
Source: Journal of the American Academy of Dermatology - Category: Dermatology Authors: Source Type: research
Source: Journal of the American Academy of Dermatology - Category: Dermatology Authors: Source Type: research
More News: Children | Cutaneous T cell lymphoma | Dermatology | Mycosis Fungoides | Pediatrics | Skin